Skip to main content
Shenyang Xingqi Pharmaceutical Co., Ltd. logo

Shenyang Xingqi Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 300573 ISIN · CNE100002DV1 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,236 across all filing types
Latest filing 2026-03-06 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300573

About Shenyang Xingqi Pharmaceutical Co., Ltd.

https://www.sinqi.com

Shenyang Xingqi Pharmaceutical Co., Ltd. specializes in the research, development, production, and sale of ophthalmic medications. The company provides a comprehensive portfolio of eye care solutions targeting conditions such as myopia, dry eye syndrome, glaucoma, and ocular infections. Key products include low-dose atropine sulfate eye drops for slowing myopia progression in children, cyclosporine eye drops for dry eye, and various anti-infective and anti-inflammatory agents. The firm operates advanced manufacturing facilities and maintains a robust R&D pipeline focused on innovative drug delivery systems and therapeutic treatments for vision health. By integrating clinical research with industrial production, the company serves as a major provider of specialized ophthalmic pharmaceuticals, addressing diverse clinical needs in the field of ophthalmology.

Recent filings

Filing Released Lang Actions
关于获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of a drug registration certificate from the National Medical Products Administration. It details the drug's specifications, approval, and risk warnings. The document is short (900 characters) and serves as a formal announcement of a regulatory approval event rather than a financial report or detailed filing. It does not contain financial data, management changes, voting results, or other report types defined in the filing categories. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-03-06 Chinese
关于变更持续督导保荐代表人的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the change of continuous supervision sponsors (保荐代表人) for a specific stock issuance project by the company. It details the replacement of individuals responsible for ongoing supervision related to a 2020 private placement of shares. The document is short (981 characters) and focuses on management changes related to sponsorship and supervision roles, not on financial results or detailed reports. This fits the category of Board/Management Information (MANG), as it announces changes in key supervisory personnel related to the company's financing activities but does not itself report financial data or results.
2026-02-11 Chinese
关于SQ-129玻璃体缓释注射液用于糖尿病性黄斑水肿Ⅰ／Ⅱ期临床试验首例受试者入组的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Shenyang Xingqi Eye Medicine Co., Ltd. regarding the enrollment of the first subject in a Phase I/II clinical trial for a drug (SQ-129) targeting diabetic macular edema. It includes details about the drug, clinical trial phase, regulatory approval number, and potential impact on the company. The document is short (1149 characters) and serves as an announcement of a clinical trial milestone rather than a financial report or detailed regulatory filing. It does not contain financial data, management changes, voting results, or other report types. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about clinical trial progress that does not fit other specific categories.
2026-02-03 Chinese
关于SQ-129玻璃体缓释注射液用于视网膜分支静脉阻塞（BRVO）或中央静脉阻塞（CRVO）引起的黄斑水肿Ⅰ／Ⅱ期临床试验首例受试者入组的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company about the enrollment of the first subject in a Phase I/II clinical trial for a new drug. It provides details about the drug, the clinical trial phase, and the potential impact on the company. The document is short (1281 characters) and does not contain financial data, financial statements, or detailed financial analysis. It is not a report but an announcement about a clinical trial milestone. There is no indication that this is a regulatory filing related to financial results, management changes, or capital updates. It fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about a clinical trial progress, which does not fit into any other specific financial or corporate filing category.
2026-01-29 Chinese
2025年度业绩预告
Earnings Release Classification · 95% confidence The document is a 2025 annual performance forecast (业绩预告) for the company, covering the period from January 1, 2025 to December 31, 2025. It provides estimated net profit figures and growth compared to the previous year. It explicitly states that the data is preliminary, unaudited, and will be detailed in the 2025 annual report. The document is short (854 characters) and serves as a performance forecast announcement rather than a full financial report. This fits the definition of an Earnings Release (ER), which is an initial announcement of periodic financial results with key highlights only. FY 2025
2026-01-22 Chinese
关于SQ-24071滴眼液获得临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a pharmaceutical company about receiving clinical trial approval from the National Medical Products Administration for a new eye drop drug. It contains no financial data, no mention of financial results, no regulatory filings related to financial reporting, and no indication of shareholder votes or management changes. The document is an announcement of a regulatory approval event related to drug development, not a financial report or meeting material. It is short (963 characters) and serves as a formal notification to investors and the public about the clinical trial approval. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-01-19 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.